Hakim Bouterfa Selected Research

177Lu-DOTA-JR11

1/2017

Biodistribution, Pharmacokinetics, and Dosimetry of 177Lu-, 90Y-, and 111In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist 177Lu-DOTATATE: The Mass Effect.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hakim Bouterfa Research Topics

Disease

6	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2018 - 10/2003
4	Neoplasms (Cancer) 01/2018 - 10/2003
2	Neoplasm Metastasis (Metastasis) 01/2018 - 08/2003
2	Acromegaly 05/2009 - 06/2007
1	Arteritis 12/2020
1	Carcinoid Tumor (Carcinoid) 04/2010
1	Adenoma (Adenomas) 05/2009
1	Renal Insufficiency (Renal Failure) 10/2004
1	Nausea 02/2004
1	Vomiting 02/2004
1	Disease Progression 10/2003

Drug/Important Bio-Agent (IBA)

4	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 01/2018 - 10/2003
4	Octreotide (Sandostatin)FDA LinkGeneric 04/2010 - 04/2006
3	Edotreotide (SMT 487)IBA 01/2018 - 10/2003
3	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2017 - 08/2003
3	Radioisotopes (Radionuclides)IBA 12/2016 - 10/2004
2	Peptide Receptors (Peptide Receptor)IBA 12/2016 - 04/2006
2	DOTA-Tyr(3)- 90Y-octreotideIBA 02/2004 - 08/2003
1	68Ga-pentixaforIBA 12/2020
1	Gallium-68IBA 12/2020
1	Fluorine-18IBA 12/2020
1	Ga(III)-DOTATOCIBA 01/2018
1	177Lu-DOTA-JR11IBA 01/2017
1	lutetium Lu 177 dotatateIBA 01/2017
1	InterferonsIBA 04/2006
1	CreatinineIBA 02/2004
1	Amino Acids FDA Link 02/2004
1	amino-acid, glucose, and electrolyte solution (Novamine)FDA Link 02/2004
1	pentetreotide (OctreoScan)FDA Link 02/2004
1	RadiopharmaceuticalsIBA 10/2003
1	Indicators and Reagents (Reagents)IBA 10/2003
1	EnzymesIBA 08/2003

Therapy/Procedure

6	Therapeutics 12/2016 - 10/2003
1	Drug Therapy (Chemotherapy) 04/2006
1	Aftercare (After-Treatment) 10/2003